Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL427229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL14379766 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL41472 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12758160 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL18537396 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3954927 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL379651 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-10918626-B2 | Method for improving pharmacokinetics | ROCHE PALO ALTO LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200230112-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | ROCHE PALO ALTO LLC (US) | 2020-07-23 | — | — | US | disclosed |
| US-20180318267-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | ROCHE PALO ALTO LLC (US) | 2018-11-08 | — | — | US | disclosed |
| EP-3362059-A1 | NEW COMBINATION THERAPIES FOR TREATING NEUROLOGICAL DAMAGE | Universitat Autònoma De Barcelona (ES) | 2018-08-22 | — | — | EP | disclosed |
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | FORESIGHT BIOTHERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| EP-2421527-B1 | METHODS FOR IMPROVING PHARMACOKINETICS | HOFFMANN LA ROCHE (CH) | 2018-06-13 | — | — | EP | disclosed |
| US-20170119739-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | ROCHE PALO ALTO LLC (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2017064317-A1 | NEW COMBINATION THERAPIES FOR TREATING NEUROLOGICAL DAMAGE | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2017-04-20 | — | — | WO | disclosed |
| US-9597351-B2 | Nano-targeted delivery of protease, polymerase inhibitors with or without immune modulators in the treatment of hepatitis C | MOUSA SHAKER A (US) | 2017-03-21 | — | — | US | disclosed |
| US-20060252785-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-11-09 | — | — | US | disclosed |
| US-20060040890-A1 | 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | disclosed |
| US-20060040927-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | disclosed |
| CN-1190198-C | Modulation of TH1/TH2 cytokine expression by Ribavirin and Ribavirin analogs in activated T lymphocytes | ICN PHARMACEUTICALS CO (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1240899-A2 | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections | ICN Pharmaceuticals, Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1174141-A2 | Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes | ICN Pharmaceuticals, Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| CN-1209747-A | Modulation of TH1/TH2 cytokine expression by Ribavirin and Ribavirin analogs in activated T lymphocytes | ICN PHARMACEUTICALS CO (US) | 1999-03-03 | — | — | CN | disclosed |
| EP-0879056-A4 | MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN-m(3) AND RIBAVIRIN-m(3) ANALOGS IN ACTIVATED T-LYMPHOCYTES | ICN PHARMACEUTICALS (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0879056-A1 | MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN$m(3) AND RIBAVIRIN$m(3) ANALOGS IN ACTIVATED T-LYMPHOCYTES | ICN Pharmaceuticals, Inc. (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997026883-A1 | MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN® AND RIBAVIRIN® ANALOGS IN ACTIVATED T-LYMPHOCYTES | ICN PHARMACEUTICALS, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | EIF2AK2, IRF3, IFNG | LMNA 2781/4885SMN1; SMN2 1375/4885ALDH1A1 1948/4885 |
| US-20060040890-A1 | 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. | HAVCR2, HCCS, CYP2S1 | LMNA 4413/4885SMN1; SMN2 3960/4885ALDH1A1 171/4885 |
| US-20060252785-A1 | Heterocyclic antiviral compounds | EIF2AK2, HAVCR2, POLR2E | LMNA 1768/4885SMN1; SMN2 3231/4885ALDH1A1 431/4885 |
| US-10918626-B2 | Method for improving pharmacokinetics | CYP3A43, CYP3A4, CYP3A5 | LMNA 4555/4885SMN1; SMN2 4215/4885ALDH1A1 215/4885 |
| US-20180318267-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | CYP3A43, CYP3A4, CYP3A5 | LMNA 4555/4885SMN1; SMN2 4215/4885ALDH1A1 215/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | LMNA 789/4885SMN1; SMN2 4179/4885ALDH1A1 4825/4885 |
| US-20200230112-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | CYP3A43, CYP3A4, CYP3A5 | LMNA 4555/4885SMN1; SMN2 4215/4885ALDH1A1 215/4885 |
| US-20060040927-A1 | Heterocyclic antiviral compounds | HAVCR2, POLR1A, HCCS | LMNA 2439/4885SMN1; SMN2 3346/4885ALDH1A1 113/4885 |
| US-20170119739-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | CYP3A43, CYP3A4, CYP3A5 | LMNA 4555/4885SMN1; SMN2 4215/4885ALDH1A1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.